The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Strategies and Approaches of Targeting STAT3 for Cancer Treatment
Abstract
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates the expression of genes related to cell cycle, cell survival, and immune response associated with cancer progression and malignancy in a number of cancer types. Once activated, STAT3 forms a homodimer and translocates to the nucleus where it binds DNA promoting the translation of target genes associated with antiapoptosis, angiogenesis, and invasion/migration. In normal cells, levels of activated STAT3 remain transient; however, STAT3 remains constitutively active in approximately 70% of human solid tumors. The pivotal role of STAT3 in tumor progression has promoted a campaign in drug discovery to identify small molecules that disrupt the function of STAT3. A range of approaches have been used to identify novel small molecule inhibitors of STAT3, including high-throughput screening of chemical libraries, computational-based virtual screening, and fragment-based design strategies. The most common approaches in targeting STAT3 activity are either via the inhibition of tyrosine kinases capable of phosphorylating and thereby activating STAT3 or by preventing the formation of functional STAT3 dimers through disruption of the SH2 domains. However, the targeting of the STAT3 DNA-binding domain and disruption of binding of STAT3 to its DNA promoter have not been thoroughly examined, mainly due to the lack of adequate assay systems. This review summarizes the development of STAT3 inhibitors organized by the approach used to inhibit STAT3, the current inhibitors of each class, and the assay systems used to evaluate STAT3 inhibition and offers an insight into future approaches for small molecule STAT3 inhibitor development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Structure and function of a new STAT-induced STAT inhibitor
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,040
Akira, S., Nishio, Y., Inoue, M., Wang, X.-J., We, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., & Kishimoto, T. (1994) · Cell · doi:10.1016/0092-8674(94)90235-6 · Cited by 1,019
Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., Senior, R. M., & Shibuya, M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00153-8 · Cited by 910
Sano, S., Chan, K. S., Carbajal, S., Clifford, J., Peavey, M., Kiguchi, K., Itami, S., Nickoloff, B. J., & DiGiovanni, J. (2005) · Nature Medicine · doi:10.1038/nm1162 · Cited by 752
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
Wu, A., Wei, J., Kong, L.-Y., Wang, Y., Priebe, W., Qiao, W., Sawaya, R., & Heimberger, A. B. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq082 · Cited by 691
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., & Jove, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107527200 · Cited by 448
Therapeutic modulators of STAT signalling for human diseases
Miklossy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 413
Targeting STAT3 in cancer: how successful are we?
Yue, P., & Turkson, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802565791 · Cited by 413
Shouda, T., Yoshida, T., Hanada, T., Wakioka, T., Oishi, M., Miyoshi, K., Komiya, S., Kosai, K.-I., Hanakawa, Y., Hashimoto, K., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13568 · Cited by 395
Stat3 regulates genes common to both wound healing and cancer
Dauer, D. J., Ferraro, B., Song, L., Yu, B., Mora, L., Buettner, R., Enkemann, S., Jove, R., & Haura, E. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208469 · Cited by 380
The myocardial JAK/STAT pathway: From protection to failure
BOENGLER, K., HILFIKERKLEINER, D., DREXLER, H., HEUSCH, G., & SCHULZ, R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.002 · Cited by 362
Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121606109 · Cited by 344
Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 283
Pang, M., Ma, L., Gong, R., Tolbert, E., Mao, H., Ponnusamy, M., Chin, Y. E., Yan, H., Dworkin, L. D., & Zhuang, S. (2010) · Kidney International · doi:10.1038/ki.2010.154 · Cited by 260
Yamamoto, T., Sekine, Y., Kashima, K., Kubota, A., Sato, N., Aoki, N., & Matsuda, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02291-x · Cited by 250
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
Buchert, M., Burns, C. J., & Ernst, M. (2016) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 243
Miyoshi, K., Takaishi, M., Nakajima, K., Ikeda, M., Kanda, T., Tarutani, M., Iiyama, T., Asao, N., DiGiovanni, J., & Sano, S. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.255 · Cited by 235
Hypoxia Potentiates Glioma-Mediated Immunosuppression
Wei, J., Wu, A., Kong, L.-Y., Wang, Y., Fuller, G., Fokt, I., Melillo, G., Priebe, W., & Heimberger, A. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016195 · Cited by 220
Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T
Zhang, X., Guo, A., Yu, J., Possemato, A., Chen, Y., Zheng, W., Polakiewicz, R. D., Kinzler, K. W., Vogelstein, B., Velculescu, V. E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611665104 · Cited by 210
Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein
Debnath, B., Xu, S., & Neamati, N. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300207s · Cited by 202
Bos, M., Mendelsohn, J. M., Kim, Y. M., Albanell, J., Fry, D. W., & Baselga, J. M. (1997) · PubMed · Cited by 199
Regulation of STAT signaling by acetylation
Zhuang, S. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.007 · Cited by 195
Lin, L., Hutzen, B., Li, P.-K., Ball, S., Zuo, M., DeAngelis, S., Foust, E., Sobo, M., Friedman, L., Bhasin, D., et al. (2010) · Neoplasia · doi:10.1593/neo.91196 · Cited by 192
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
STAT inhibitors for cancer therapy
Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-90 · Cited by 187
Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179
Carvalho da Fonseca, A. C., & Badie, B. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/264124 · Cited by 174
Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir
HIRANO, T. (2010) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.86.717 · Cited by 172
Obana, M., Maeda, M., Takeda, K., Hayama, A., Mohri, T., Yamashita, T., Nakaoka, Y., Komuro, I., Takeda, K., Matsumiya, G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.893677 · Cited by 172
Kim, H., & Baumann, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5326 · Cited by 170
Furqan, M., Mukhi, N., Lee, B., & Liu, D. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-5 · Cited by 170
Selective JAK inhibitors in development for rheumatoid arthritis
Norman, P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918604 · Cited by 158
Current status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease
Carey, R. G., Jurickova, I., Ballard, E. T., Bonkowski, E. L., Han, X., Xu, H., & Denson, L. A. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20342 · Cited by 155
Turkson, J., Zhang, S., Mora, L. B., Burns, A. C., Sebti, S. M., & Jove, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502694200 · Cited by 153
Zhang, X., Sun, Y., Pireddu, R., Yang, H., Urlam, M. K., Lawrence, H. R., Guida, W. C., Lawrence, N. J., & Sebti, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3175 · Cited by 149
Eiring, A. M., Page, B. D. G., Kraft, I. L., Mason, C. C., Vellore, N. A., Resetca, D., Zabriskie, M. S., Zhang, T. Y., Khorashad, J. S., Engar, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.245 · Cited by 141
Nagel‐Wolfrum, K., Buerger, C., Wittig, I., Butz, K., Hoppe‐Seyler, F., & Groner, B. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.170.2.3 · Cited by 133
Development of a Highly Selective c-Src Kinase Inhibitor
Brandvold, K. R., Steffey, M. E., Fox, C. C., & Soellner, M. B. (2012) · ACS Chemical Biology · doi:10.1021/cb300172e · Cited by 130
Huang, W., Dong, Z., Wang, F., Peng, H., Liu, J., & Zhang, J. (2014) · ACS Chemical Biology · doi:10.1021/cb500071v · Cited by 128
The role of Stat3 in glioblastoma multiforme
Luwor, R. B., Stylli, S. S., & Kaye, A. H. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.03.006 · Cited by 127
Xu, S., Grande, F., Garofalo, A., & Neamati, N. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1082 · Cited by 125
Huang, W., Dong, Z., Chen, Y., Wang, F., Wang, C. J., Peng, H., He, Y., Hangoc, G., Pollok, K. E., Sandusky, G. E., et al. (2015) · Oncogene · doi:10.1038/onc.2015.215 · Cited by 116
Progress towards the development of SH2 domain inhibitors
Kraskouskaya, D., Duodu, E., Arpin, C. C., & Gunning, P. T. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35449k · Cited by 115
AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
Plimack, E. R., LoRusso, P. M., Mccoon, P. E., Tang, W., Krebs, A. D., Curt, G. A., & Eckhardt, S. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0198 · Cited by 115
Schust, J., & Berg, T. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.03.024 · Cited by 110
A New Small-Molecule Stat3 Inhibitor
McMurray, J. S. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.11.001 · Cited by 106
Activation of epithelial STAT3 regulates intestinal homeostasis
Neufert, C. F., Pickert, G., Zheng, Y., Wittkopf, N., Warntjen, M., Nikolae, A., Ouyang, W., Neurath, M. F., & Becker, C. (2010) · Cell Cycle · doi:10.4161/cc.9.4.10615 · Cited by 105
A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130
Hong, S., Choi, J. H., Lee, S. Y., Park, Y.-H., Park, K.-Y., Lee, J. Y., Kim, J., Gajulapati, V., Goo, J.-I., Singh, S., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402908 · Cited by 104
Bousquet, C., Susini, C., & Melmed, S. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7924 · Cited by 102
Li, S. Q., Cheuk, A., Shern, J. F., Song, Y., Hurd, L., Liao, H., Wei, J. S., & Khan, J. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076551 · Cited by 102
Qu, P., Roberts, J., Yuan, L., Albrecht, M. E., Cummings, O. W., Eble, J. N., Du, H., & Yan, C. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.025 · Cited by 99
Wang, P., Yang, F., Du, H., Guan, Y., Xu, T., Xu, X., Su, D., & Miao, C. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.000134 · Cited by 99
Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells
Don‐Doncow, N., Escobar, Z., Johansson, M., Kjellström, S., Garcia, V., Muñóz, E., Sterner, O., Bjartell, A. S., & Hellsten, R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564252 · Cited by 98
Nucleocytoplasmic shuttling of persistently activated STAT3
Herrmann, A., Vogt, M., Mönnigmann, M., Clahsen, T., Sommer, U., Haan, S., Poli, V., Heinrich, P. C., & Müller-Newen, G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03482 · Cited by 94
Chen, C., Loy, A., Cen, L., Chan, C., Hsieh, F.-C., Cheng, G., Wu, B., Qualman, S. J., Kunisada, K., Yamauchi‐Takihara, K., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-111 · Cited by 91
de Groot, J., Liang, J., Kong, L.-Y., Wei, J., Piao, Y., Fuller, G. N., Qiao, W., & Heimberger, A. B. (2012) · Oncotarget · doi:10.18632/oncotarget.663 · Cited by 90
Design, synthesis, and studies of small molecule STAT3 inhibitors
Bhasin, D. K., Cisek, K. K., Pandharkar, T., Regan, N., Li, C., Pandit, B., Lin, J., & Li, P. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.031 · Cited by 88
Fletcher, S., Singh, J., Zhang, X., Yue, P., Page, B. D. G., Sharmeen, S., Shahani, V. M., Zhao, W. M., Schimmer, A. D., Turkson, J., et al. (2009) · ChemBioChem · doi:10.1002/cbic.200900172 · Cited by 88
Activation of PPARβ/δ Causes a Psoriasis-Like Skin Disease In Vivo
Romanowska, M., Reilly, L., Palmer, C. N. A., Gustafsson, M. C. U., & Foerster, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009701 · Cited by 86
gp130: a promising drug target for cancer therapy
Xu, S., & Neamati, N. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.830105 · Cited by 83
Small Molecule Inhibitors of STAT3 for Cancer Therapy
Zhao, M. L., Jiang, B., & Gao, F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796957284 · Cited by 82
Junicho, A., Matsuda, T., Yamamoto, T., Kishi, H., Korkmaz, K., Saatcioglu, F., Fuse, H., & Muraguchi, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3753 · Cited by 81
Mankan, A. K., & Greten, F. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601739 · Cited by 77
Nam, S., Wen, W. X., Schroeder, A., Herrmann, A., Yu, H., Cheng, X., Merz, K., Eisenbrand, G., Li, H., Yuan, Y., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.013 · Cited by 75
Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Griesinger, A. M., Josephson, R. J., Donson, A. M., Levy, J. M. M., Amani, V. M., Birks, D. K., Hoffman, L. M., Furtek, S. L., Reigan, P., Handler, M. H., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0061 · Cited by 75
Self-citationMair, M., Zollner, G., Schneller, D., Musteanu, M., Fickert, P., Gumhold, J., Schuster, C., Fuchsbichler, A., Bilban, M., Tauber, S., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.049 · Cited by 75
Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer
Ji, T., Gong, D., Han, Z., Xiao, W., Yan, Y., Ye, F., Ding, W., Wang, J., Xia, X., Li, F., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.022 · Cited by 74
Ball, S. L., Li, C., Li, P., & Lin, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018820 · Cited by 70
Lin, L., Benson, D. M., DeAngelis, S., Bakan, C. E., Li, P., Li, C., & Lin, J. (2012) · International Journal of Cancer · doi:10.1002/ijc.26152 · Cited by 66
Targeting Sh2 Domains in Breast Cancer
Morlacchi, P., Robertson, F. M., Klostergaard, J., & McMurray, J. S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.120 · Cited by 63
STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma
Zhang, Q., Zhang, C., He, J., Guo, Q., Hu, D., Yang, X., Wang, J., Kang, Y., She, R., Wang, Z., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2823-y · Cited by 61
Page, B. D. G., Fletcher, S., Yue, P., Li, Z., Zhang, X., Sharmeen, S., Datti, A., Wrana, J. L., Trudel, S., Schimmer, A. D., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.056 · Cited by 60
The role of STAT3 activation in modulating the immune microenvironment of GBM
See, A. P., Han, J. E., Phallen, J. A., Binder, Z. A., Gallia, G. L., Pan, F., Jinasena, D., Jackson, C. M., Belcaid, Z., Jeong, S. J., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0981-6 · Cited by 58
Novel high-throughput screening system for identifying STAT3–SH2 antagonists
Uehara, Y., Mochizuki, M., Matsuno, K., Haino, T., & Asai, A. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.137 · Cited by 58
Heidelberger, S., Zinzalla, G., Antonow, D., Essex, S., Piku Basu, B., Palmer, J., Husby, J., Jackson, P. J. M., Rahman, K. M., Wilderspin, A. F., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.066 · Cited by 52
Gunning, P. T., Glenn, M. P., Siddiquee, K., Katt, W. P., Masson, E., Sebti, S. M., Turkson, J., & Hamilton, A. D. (2008) · ChemBioChem · doi:10.1002/cbic.200800291 · Cited by 51
Park, I., & Li, C. (2010) · Journal of Molecular Recognition · doi:10.1002/jmr.1047 · Cited by 50
Resetca, D., Haftchenary, S., Gunning, P. T., & Wilson, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595454 · Cited by 47
Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma
Mochizuki, D., Adams, A., Warner, K. A., Zhang, Z., Pearson, A. T., Misawa, K., McLean, S. A., Wolf, G. T., & Nor, J. E. (2015) · Oncotarget · doi:10.18632/oncotarget.4477 · Cited by 45
Song, S.-N. J., & Yoshizaki, K. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.992779 · Cited by 45
Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis
Bai, A., Hu, P., Chen, J., Song, X., Chen, W., Peng, W., Zeng, Z., & Gao, X. (2006) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0229-z · Cited by 42
BART is essential for nuclear retention of STAT3
Muromoto, R., Sekine, Y., Imoto, S., Ikeda, O., Okayama, T., Sato, N., & Matsuda, T. (2008) · International Immunology · doi:10.1093/intimm/dxm154 · Cited by 39
Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression
Yokogami, K., Yamashita, S., & Takeshima, H. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0122-0 · Cited by 37
Liu, A., Liu, Y., Li, P., Li, C., & Lin, J. (2011) · PubMed · Cited by 32
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
Heine, A., Held, S. A. E., Daecke, S. N., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128897 · Cited by 31
Liu, L., Gaboriaud‐Kolar, N., Vougogiannopoulou, K., Tian, Y., Wu, J., Wen, W. X., Skaltsounis, A., & Jove, R. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26721 · Cited by 30
Mencalha, A. L., Rocher, B. D., Salles, D. C., Binato, R., & Abdelhay, E. S. F. W. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1109-3 · Cited by 28
HIC1 interacts with and modulates the activity of STAT3
Lin, Y.-M., Wang, C.-M., Jeng, J., Leprince, D., & Shih, H. (2013) · Cell Cycle · doi:10.4161/cc.25365 · Cited by 24
Development of new N-arylbenzamides as STAT3 dimerization inhibitors
Urlam, M. K., Pireddu, R., Ge, Y., Zhang, X., Sun, Y., Lawrence, H. R., Guida, W. C., Sebti, S. M., & Lawrence, N. J. (2013) · MedChemComm · doi:10.1039/c3md20323a · Cited by 22
Kim, B., Lee, Y., Yoo, H., Cui, M., Lee, S., Kim, S. Y., Cho, J. U., Lee, H., Yang, B., Kwon, Y., et al. (2015) · Experimental Dermatology · doi:10.1111/exd.12698 · Cited by 13
Cited by
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Role of STAT3 signaling pathway in breast cancer
Ma, J.-H., Qin, L., & Li, X. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0527-z · Cited by 420
Chemotherapy: a double-edged sword in cancer treatment
Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 397
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 396
Chakraborty, D., Šumová, B., Mallano, T., Chen, C.-W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01236-6 · Cited by 356
Metadata
- Authors
- Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-01-15
- Volume
- 11
- Issue
- 2
- Pages
- 308-318
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W2230354098
- Cited by
- 347
- References
- 102
- FWCI
- 19.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.